Looking to connect with leading drug developers and discover next-generation therapeutics redefining neurodegenerative treatment? 

Look no further than the Alzheimer’s & Parkinson’s Drug Development Summit 2026. Now in its’ 14th year, the Alzheimer’s & Parkinson’s Drug Development Summit returns to Boston in 2026 and will unite global leaders from pharma, biotech, and academia to shape the next generation of neurodegenerative therapies. 

As the only industry-focused and end-to-end meeting, with comprehensive coverage spanning early discovery through to late clinical and regulatory, this hight-impact three-day event is specifically curated to explore disease progression, modification and prodromal intervention, so the next generation of therapeutics can prevent as well provide a meaningful impact to neurodegenerative patients in need. 

The 14th Alzheimer’s & Parkinson’s Drug Development Summit will feature: 

• 2 deep dive workshops into in vivo and in vitro modelling advancements 
• Seminar day on fluid-based biomarker innovation 
• 40+ expert speakers including industry leaders, academic KOLs and patient voices 
• Multiple tracks of content spanning discovery, preclinical, clinical and regulatory 
• 10+ hours dedicated networking time. 

See the full event guide for more details -  https://ter.li/ks90ii